深圳格莱恩生物医药科技

Grain Biopharmaceutical (Shenzhen) Co., Ltd. is a clinical-stage biotechnology company based in Shenzhen, China, focused on the discovery and development of innovative small molecule therapeutics. Founded in 2021, the company targets high-value pathways in oncology and autoimmune diseases to address significant unmet medical needs. Its lead program, GRN-007, is a novel small molecule inhibitor currently in Phase 1 clinical development for advanced solid tumors. The company leverages a proprietary drug discovery platform and has received strategic investment from prominent firms such as Shenzhen Capital Group. Grain Biopharmaceutical is committed to advancing a diverse pipeline of next-generation drugs through internal R&D and strategic collaborations.